Matthew B Schabath1, Anthony Nguyen2, Patrick Wilson3, Katelyn R Sommerer4, Zachary J Thompson5, Alberto A Chiappori6. 1. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. Electronic address: Matthew.Schabath@Moffitt.org. 2. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States; University of South Florida, College of Public Health, Tampa, FL, United States. 3. University of South Florida, College of Public Health, Tampa, FL, United States. 4. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 5. Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 6. Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Abstract
OBJECTIVES: An assessment of temporal trends in patient survival is important to determine the progress toward patient outcomes and to reveal where advancements must be made. This study assessed temporal changes spanning 22years in demographics, clinical characteristics, and overall survival of small cell lung cancer (SCLC) patients. MATERIALS AND METHODS: This analysis included 1032 SCLC patients spanning two time-periods from the H. Lee Moffitt Cancer Center and Research Institute: 1986-1999 (N=410) and 2000-2008 (N=622). Kaplan-Meier survival curves and log-rank statistics were used to assess survival rates across the two time-periods and multivariable Cox proportional hazards models were used to generate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: The overall 5-year survival rate significantly increased from 8.3% for the 1986-1999 time-period to 11.0% (P<0.001) for the 2000-2008 time-period, and the median survival time increased from 11.3months (95% CI 10.5-12.7) to 15.2months (95% CI 13.6-16.6). We also observed significant increases in stage-specific median survival times and survival rates across the two time-periods. A multivariable Cox proportional hazards model for the entire cohort revealed significant increased risk of death for patients diagnosed in 1986-1999 (HR=1.29; 95% CI 1.11-1.49), patients diagnosed between 60 and 69years of age (HR=1.33; 95% CI 1.04-1.49) and over 70years of age (HR=1.63; 95% CI 1.26-2.11), men (HR=1.33; 95% CI 1.16-1.53), patients with no first course treatment (HR=2.17; 95% CI 1.57-3.00) and extensive stage SCLC (HR=2.79; 95% CI 2.35-3.30). CONCLUSION: This analysis demonstrated significant improvements in overall and stage-specific median survival times and survival rates of SCLC patients treated at the Moffitt Cancer Center from 1986 to 2008.
OBJECTIVES: An assessment of temporal trends in patient survival is important to determine the progress toward patient outcomes and to reveal where advancements must be made. This study assessed temporal changes spanning 22years in demographics, clinical characteristics, and overall survival of small cell lung cancer (SCLC) patients. MATERIALS AND METHODS: This analysis included 1032 SCLCpatients spanning two time-periods from the H. Lee Moffitt Cancer Center and Research Institute: 1986-1999 (N=410) and 2000-2008 (N=622). Kaplan-Meier survival curves and log-rank statistics were used to assess survival rates across the two time-periods and multivariable Cox proportional hazards models were used to generate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: The overall 5-year survival rate significantly increased from 8.3% for the 1986-1999 time-period to 11.0% (P<0.001) for the 2000-2008 time-period, and the median survival time increased from 11.3months (95% CI 10.5-12.7) to 15.2months (95% CI 13.6-16.6). We also observed significant increases in stage-specific median survival times and survival rates across the two time-periods. A multivariable Cox proportional hazards model for the entire cohort revealed significant increased risk of death for patients diagnosed in 1986-1999 (HR=1.29; 95% CI 1.11-1.49), patients diagnosed between 60 and 69years of age (HR=1.33; 95% CI 1.04-1.49) and over 70years of age (HR=1.63; 95% CI 1.26-2.11), men (HR=1.33; 95% CI 1.16-1.53), patients with no first course treatment (HR=2.17; 95% CI 1.57-3.00) and extensive stage SCLC (HR=2.79; 95% CI 2.35-3.30). CONCLUSION: This analysis demonstrated significant improvements in overall and stage-specific median survival times and survival rates of SCLCpatients treated at the Moffitt Cancer Center from 1986 to 2008.
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Patrick Micke; Andreas Faldum; Tsegay Metz; Kai-Michael Beeh; Fernando Bittinger; Jan-Georg Hengstler; Roland Buhl Journal: Lung Cancer Date: 2002-09 Impact factor: 5.705
Authors: B J Slotman; C Faivre-Finn; G W P M Kramer; E Rankin; M Snee; M Hatton; P E Postmus; L Collette; E Musat; S Senan Journal: Ned Tijdschr Geneeskd Date: 2008-04-26
Authors: Nathan R Foster; Lindsay A Renfro; Steven E Schild; Mary W Redman; Xiaofei F Wang; Suzanne E Dahlberg; Keyue Ding; Penelope A Bradbury; Suresh S Ramalingam; David R Gandara; Taro Shibata; Nagahiro Saijo; Everett E Vokes; Alex A Adjei; Sumithra J Mandrekar Journal: J Thorac Oncol Date: 2015-07 Impact factor: 15.609
Authors: Jeffrey A Kern; Jihye Kim; Daniel G Foster; Rangnath Mishra; Eric E Gardner; John T Poirier; Christopher Rivard; Hui Yu; James H Finigan; Afshin Dowlati; Charles M Rudin; Aik-Choon Tan Journal: J Thorac Oncol Date: 2020-06-26 Impact factor: 15.609